Review Article

J Rheum Dis 2012; 19(2): 67-72

Published online April 30, 2012

© Korean College of Rheumatology

류마티스질환에서 B 세포 표적 치료

서창희

아주대학교 의과대학 류마티스내과학교실

B Cell Targeted Therapy in Rheumatic Disease

Chang-Hee Suh

Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea

Correspondence to : Chang-Hee Suh

Abstract

B cells play an important role in the pathogenesis of autoimmune disease. B cells not only produce pathogenic autoantibodies, but also present self-antigens to T cells and provide costimulatory signals for self-reactiveT cells. Recently, biologics have been tried in several autoimmune diseases as immune modulators with some promising results. Among them, several biologic agents that target B cells have led to improved patients' outcomes and quality of life in patients with rheumatoid arthritis and systemic lupus erythematosus. These agents either deplete B cells by targeting B cell surface antigens, such as CD20 and CD22, or block B cell survival by inhibiting the activity of B cell survival factors, such as BLyS and APRIL. Initially, I discuss briefly the role of B cells in driving autoimmune diseases, and then focus on the efficacy and safety data of the B cell-targeted therapy in rheumatoid arthritis and systemic lupus erythematosus.

Keywords B cell, Target, Treatment, Rheumatoid arthritis, Lupus

Article

Review Article

J Rheum Dis 2012; 19(2): 67-72

Published online April 30, 2012

Copyright © Korean College of Rheumatology.

류마티스질환에서 B 세포 표적 치료

서창희

아주대학교 의과대학 류마티스내과학교실

B Cell Targeted Therapy in Rheumatic Disease

Chang-Hee Suh

Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea

Correspondence to:Chang-Hee Suh

Abstract

B cells play an important role in the pathogenesis of autoimmune disease. B cells not only produce pathogenic autoantibodies, but also present self-antigens to T cells and provide costimulatory signals for self-reactiveT cells. Recently, biologics have been tried in several autoimmune diseases as immune modulators with some promising results. Among them, several biologic agents that target B cells have led to improved patients' outcomes and quality of life in patients with rheumatoid arthritis and systemic lupus erythematosus. These agents either deplete B cells by targeting B cell surface antigens, such as CD20 and CD22, or block B cell survival by inhibiting the activity of B cell survival factors, such as BLyS and APRIL. Initially, I discuss briefly the role of B cells in driving autoimmune diseases, and then focus on the efficacy and safety data of the B cell-targeted therapy in rheumatoid arthritis and systemic lupus erythematosus.

Keywords: B cell, Target, Treatment, Rheumatoid arthritis, Lupus

JRD
Jan 01, 2025 Vol.32 No.1, pp. 1~7
COVER PICTURE
Cumulative growth of rheumatology members and specialists (1980~2024). Cumulative distribution of the number of the (A) Korean College of Rheumatology members and (B) rheumatology specialists. (J Rheum Dis 2025;32:63-65)

Stats or Metrics

Share this article on

  • line

Related articles in JRD

Journal of Rheumatic Diseases

pISSN 2093-940X
eISSN 2233-4718
qr-code Download